Altimmune, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-27$6.18 RISE2026-04-30$2.60 PEAK2026-05-06$3.26 99d | -57.9% 93d | Missed | Missed | — | — | +25.4% 6d | Missed |
DROP2025-12-08$5.61 RISE2026-01-02$3.51 PEAK2026-01-27$6.18 50d | -37.4% 25d | Missed | Missed | — | — | +76.1% 25d | Missed |
DROP2025-07-02$4.90 RISE2025-11-05$3.75 PEAK2026-01-27$6.18 209d | -23.5% 126d | Missed | Missed | — | — | +64.8% 83d | Missed |
DROP2025-06-25$7.71 RISE2025-08-11$3.38 PEAK2025-10-27$4.14 124d | -56.2% 47d | Missed | Missed | — | — | +22.5% 77d | Missed |
DROP2025-06-25$7.71 RISE2025-06-27$3.50 PEAK2025-07-02$4.90 7d | -54.6% 2d | Missed | Missed | — | — | +40.0% 5d | Missed |
DROP2024-12-04$9.85 RISE2025-04-08$3.67 PEAK2025-06-25$7.71 203d | -62.7% 125d | Missed | Missed | — | — | +110.1% 78d | Missed |
DROP2024-07-16$8.10 RISE2024-10-10$6.02 PEAK2024-12-04$9.85 141d | -25.7% 86d | Missed | Missed | — | — | +63.6% 55d | Missed |
DROP2024-04-01$10.23 RISE2024-08-07$5.50 PEAK2024-09-13$7.88 165d | -46.2% 128d | Missed | Missed | — | — | +43.3% 37d | Missed |
DROP2024-02-27$13.81 RISE2024-06-18$5.91 PEAK2024-07-16$8.10 140d | -57.2% 112d | Missed | Missed | — | — | +37.1% 28d | Missed |
DROP2024-02-27$13.81 RISE2024-04-29$6.40 PEAK2024-05-16$8.90 79d | -53.7% 62d | Missed | Missed | — | — | +39.2% 17d | Missed |
DROP2024-01-12$12.00 RISE2024-02-21$8.22 PEAK2024-02-27$13.81 46d | -31.5% 40d | Missed | Missed | — | — | +68.0% 6d | Missed |
DROP2023-06-21$4.19 RISE2023-10-23$2.14 PEAK2024-01-12$12.00 205d | -48.9% 124d | Missed | Missed | — | — | +460.7% 81d | Missed |
DROP2023-04-19$5.97 RISE2023-08-28$2.40 PEAK2023-09-15$2.92 149d | -59.8% 131d | Missed | Missed | — | — | +21.7% 18d | Missed |
DROP2023-04-19$5.97 RISE2023-08-25$2.40 PEAK2023-09-15$2.92 149d | -59.8% 128d | Missed | Missed | — | — | +21.7% 21d | Missed |
DROP2023-01-12$16.83 RISE2023-04-05$3.87 PEAK2023-04-19$5.97 97d | -77.0% 83d | Missed | Missed | — | — | +54.3% 14d | Missed |
1–15 / 26 1 / 2 | |||||||
No scored news yet for a sentiment trend.
The data are being presented today and Friday in poster sessions, including a late-breaking poster presentation, at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona, Spain.
ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data fueling investor focus.
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $25 to $20.
ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.
ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.
Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target from $14 to $11.
Altimmune, Inc. (ALT) Q1 2026 Earnings Call May 13, 2026 8:30 AM EDTCompany ParticipantsLuis SanayJerome Durso - Chairman, CEO & PresidentChristophe...
Altimmune Inc (ALT) reports a robust cash balance and strategic progress in clinical trials, despite increased expenses and net loss.
Altimmune Inc (ALT) reports a robust cash balance and strategic progress in clinical trials, despite increased expenses and net loss.
Before we begin, I would like to remind everyone that remarks made about future expectations, plans and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.
Before we begin, I would like to remind everyone that remarks made about future expectations, plans and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.
Moby summary of Altimmune, Inc.'s Q1 2026 earnings call
Moby summary of Altimmune, Inc.'s Q1 2026 earnings call
Presentation Operator MessageOperator Good morning, ladies and gentlemen, and welcome to the Altimmune First Quarter 2026 Financial Results Conference Call. [Operator Instructions] As a reminder,
Altimmune (NASDAQ:ALT) said it has strengthened its balance sheet and is preparing to begin a global Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, in the second half of 2026, as the company reported first-quarter financial results and provided updates acr
Altimmune (NASDAQ:ALT) said it has strengthened its balance sheet and is preparing to begin a global Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, in the second half of 2026, as the company reported first-quarter financial results and provided updates acr
On Wednesday, Altimmune (NASDAQ:ALT) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. View the webcast at https://edge.media-server.com/mmc/p/fpkn4a66/ Summary Altimmune reported a cash balance of approximately $535 million, boosting financial resources through a successful public
On Wednesday, Altimmune (NASDAQ:ALT) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. View the webcast at https://edge.media-server.com/mmc/p/fpkn4a66/ Summary Altimmune reported a cash balance of approximately $535 million, boosting financial resources through a successful public
Shares of Altimmune (NASDAQ:ALT) rose more than 3% in premarket trading on Wednesday after the company reported a smaller-than-expected first-quarter loss. The stock gained 3.
Shares of Altimmune (NASDAQ:ALT) rose more than 3% in premarket trading on Wednesday after the company reported a smaller-than-expected first-quarter loss. The stock gained 3.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ALT | +8.16% | -26.68% | -15.51% | -43.83% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +5.19% | -20.97% | -12.07% | -56.52% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 7.15M | $22.01M | 0.00% | Added+39.6% | 2026-03-31 |
| TwoSigma | quant | 2.48M | $7.64M | 0.01% | Added+95.9% | 2026-03-31 |
| DEShaw | quant | 727.0K | $2.24M | 0.00% | Trimmed-45.9% | 2026-03-31 |
| FidelityFMR | fundamental | 674.0K | $2.08M | 0.00% | Added+19.5% | 2026-03-31 |
| Citadel | multi-strat | 665.3K | $2.05M | 0.00% | New | 2026-03-31 |
| Wellington | fundamental | 248.2K | $764.33K | 0.00% | Trimmed-3.5% | 2026-03-31 |
| TRowePrice | fundamental | 92.5K | $285 | 0.00% | Added+85.5% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-11upcoming | -0.16 | — | — |
| 2026-05-13 | -0.25 | -0.18 | +28.00% |
| 2026-03-05 | -0.24 | -0.27 | -13.39% |
| 2025-11-06 | -0.27 | -0.21 | +20.97% |
| 2025-08-12 | -0.32 | -0.27 | +15.77% |
| 2025-05-13 | -0.34 | -0.26 | +23.91% |
| 2025-02-27 | -0.34 | -0.33 | +1.52% |
| 2024-11-12 | -0.36 | -0.32 | +10.49% |
| 2024-08-08 | -0.34 | -0.35 | -1.45% |
| 2024-05-09 | -0.35 | -0.34 | +3.55% |
| 2024-03-27 | -0.38 | -0.33 | +14.20% |
| 2023-11-07 | -0.44 | -0.39 | +11.70% |
| 2023-08-10 | -0.46 | -0.32 | +30.93% |
| 2023-05-11 | -0.48 | -0.40 | +16.67% |
| 2023-02-28 | -0.54 | -0.44 | +17.91% |
| 2022-11-10 | -0.51 | -0.48 | +5.42% |